Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Surgery is the mainstay of treatment for non-small cell lung cancer, but the decline in pulmonary function after surgery is noticeable and requires attention. This study aimed to evaluate longitudinal changes in pulmonary function and integrated patient-reported outcomes (PROs) after lung cancer surgery.

Methods: Data were obtained from a prospective cohort study, the Coordinate Approach to Cancer Patients' Health for Lung Cancer. Changes in forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV) at 2 weeks, 6 months, and 1 year after surgery, and the corresponding modified Medical Research Council (mMRC) dyspnea scale and chronic obstructive lung disease assessment test (CAT) scores were evaluated. Mixed effects model was used to investigate changes in pulmonary function and PROs.

Results: Among 620 patients, 477 (76.9%) underwent lobectomy, whereas 120 (19.4%) and 23 (3.7%) were treated with wedge resection/segmentectomy and bilobectomy/pneumonectomy, respectively. Both FVC and FEV markedly decreased 2 weeks after surgery and improved thereafter; however, they did not recover to baseline values. The corresponding mMRC dyspnea scale and CAT scores worsened immediately after surgery. The dyspnea scale of the mMRC was still higher, while CAT scores returned to baseline one year after surgery, although breathlessness and lack of energy persisted. Compared to the changes from baseline of FVC and FEV in patients who underwent lobectomy, patients who underwent bilobectomy/pneumonectomy showed a greater decrease in FVC and FEV, while wedge resection/segmentectomy patients had smaller decreases in FVC and FEV at 2 weeks, 6 months, and 1 year after surgery. Bilobectomy/pneumonectomy patients had the highest mMRC dyspnea grade among the three groups, but the difference was not statistically significant one year after surgery.

Conclusions: After lung cancer surgery, pulmonary function and PROs noticeably decreased in the immediate post-operative period and improved thereafter, except for dyspnea and lack of energy. Proper information on the timeline of changes in lung function and symptoms following lung cancer surgery could guide patient care approaches after surgery.

Trial Registration: ClinicalTrials.gov; No.: NCT03705546; URL: www.

Clinicaltrials: gov.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429784PMC
http://dx.doi.org/10.1186/s12931-022-02149-9DOI Listing

Publication Analysis

Top Keywords

lung cancer
24
pulmonary function
20
fvc fev
16
changes pulmonary
12
cancer surgery
12
mmrc dyspnea
12
dyspnea scale
12
cat scores
12
surgery
10
longitudinal changes
8

Similar Publications

Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.

Ann Surg Oncol

September 2025

Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.

Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.

Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.

View Article and Find Full Text PDF

Objectives: To quantify intraoperative pulmonary arterial catheter (PAC) use during cardiac surgery and identify hospital-, anesthesiologist-, and patient-level factors associated with PAC utilization.

Design: A cross-sectional, observational study using generalized logistic mixed models to examine variations in PAC use.

Setting: Fifty-three US academic hospitals participating in the Multicenter Perioperative Outcomes Group (MPOG) national registry PARTICIPANTS: 145,343 adult patients undergoing cardiac surgery between January 1, 2016, and December 31, 2022.

View Article and Find Full Text PDF

KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.

Crit Rev Oncol Hematol

September 2025

Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier

Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.

View Article and Find Full Text PDF

Background: Up to 70% of lung cancer may be malnourished. This study aims to examine the effects of malnutrition on outcomes in lung cancer patients undergoing resection using modified GLIM criteria.

Methods: The study utilized the mGLIM criteria to identify malnourished patients.

View Article and Find Full Text PDF

Purpose: To examine the effectiveness of virtual reality (VR)-guided imagery relaxation (VRGI) intervention in reducing anxiety among lung cancer surgery patients.

Methods: A randomized clinical trial was conducted at the Fourth Affiliated Hospital of Hebei Medical University (Shijiazhuang, Hebei, China) to recruit patients scheduled for their first elective endoscopic lung cancer surgery under general anesthesia between December 2023 and March 2024. Patients were randomly assigned in a 1:1 ratio to either the control group, receiving routine treatment and staged care in thoracic surgery, or the experimental group, receiving VRGI intervention in addition to the control group's protocol.

View Article and Find Full Text PDF